Key result
Community pharmacists with access to eGFR identified 54.0% of clinically relevant drug-related problems in elderly patients with CKD, compared to 84.7% identified by expert pharmacists.
Why the study?
Although shared electronic health records increasingly make eGFR available to community pharmacists, the skills needed to detect and manage clinically relevant drug-related problems in renal impairment are poorly documented.
Does the availability of eGFR to community pharmacists improve the detection of clinically relevant drug-related problems in elderly patients with chronic kidney disease?
Observational (n=442)
Does the availability of eGFR to community pharmacists improve the detection of clinically relevant drug-related problems in elderly patients with chronic kidney disease?
Absolute Event Rate: 54% vs 84.7%
Systematic availability of eGFR to community pharmacists positively impacts the detection of clinically relevant drug-related problems in elderly patients with renal impairment.
Access to eGFR may help CPs detect DRPs in elderly CKD patients; leaves open impact on clinical outcomes.
Community pharmacists (CPs) have traditionally had limited access to patients’ estimated glomerular filtration rate (eGFR) during the medication-dispensing process. The increasing access to shared electronic health records is making eGFR available, but the skills needed to detect and manage clinically relevant drug-related problems (DRPs) are poorly documented. The primary objective of this study was to investigate the role of CPs in the medication-dispensation process for elderly patients with renal impairment. A total of 70 CPs participated in this 6 month study. Community pharmacists asked all patients ≥65 years to bring their laboratory test values for the next medication-dispensing process. Drug-related problem detection rates were compared between CPs (prospective period) and expert pharmacists (retrospectively). The clinical relevance of each DRP was assessed by nephrologists and general practitioners using an appropriate tool. Community pharmacists recruited n = 442 patients with eGFR < 60 mL/min/1.73 m2 and detected n = 99 DRPs, whereas expert pharmacists detected n = 184 DRPs. The most frequently detected DRPs were dosage problems and contraindications. According to assessment by clinicians, CPs and expert pharmacists identified 54.0% and 84.7% of clinically relevant DRPs, respectively. This study suggests a positive impact of the systematic availability of eGFR to CPs on the detection of several DRPs with clinical relevance.
No takes yet. Share an insight, caveat, or question.
Mongaret et al. (2020) conducted an observational in Chronic Kidney Disease (n=442). Community pharmacist review with eGFR access vs. Expert pharmacist review (retrospective) was evaluated on Detection of clinically relevant drug-related problems (DRPs). Community pharmacists with access to eGFR identified 54.0% of clinically relevant drug-related problems in elderly patients with CKD, compared to 84.7% identified by expert pharmacists.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: